| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new research agenda to combat antimicrobial resistance
|
Jesudason, Timothy
|
|
|
23 |
8 |
p. e281
|
artikel
|
| 2 |
A new toolkit for WASH programmes
|
Jesudason, Timothy
|
|
|
23 |
8 |
p. e280
|
artikel
|
| 3 |
A novel Rift Valley fever vaccine
|
Bronder, Saskia
|
|
|
23 |
8 |
p. 887-889
|
artikel
|
| 4 |
A tale of two pandemics
|
Warren, Sylvia
|
|
|
23 |
8 |
p. 900
|
artikel
|
| 5 |
Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
|
Solera, Javier T
|
|
|
23 |
8 |
p. e266-e267
|
artikel
|
| 6 |
Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
|
Vasin, Andrey V
|
|
|
23 |
8 |
p. 880-881
|
artikel
|
| 7 |
Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): a pragmatic, open-label, randomised controlled trial
|
Brendish, Nathan J
|
|
|
23 |
8 |
p. 945-955
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2023; 23: e259–65
|
|
|
|
23 |
8 |
p. e279
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2023; published online https://doi.org/10.1016/S1473-3099(22)00877-5
|
|
|
|
23 |
8 |
p. e279
|
artikel
|
| 10 |
1 + 1 dose schedule for pneumococcal child vaccination: new normal?
|
Slotved, Hans-Christian
|
|
|
23 |
8 |
p. 884-885
|
artikel
|
| 11 |
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
|
Arbel, Ronen
|
|
|
23 |
8 |
p. 914-921
|
artikel
|
| 12 |
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
|
Stoliaroff-Pepin, Anna
|
|
|
23 |
8 |
p. 881-882
|
artikel
|
| 13 |
Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial
|
Temple, Beth
|
|
|
23 |
8 |
p. 933-944
|
artikel
|
| 14 |
Fractional dose yellow fever vaccination, coming of age
|
Roukens, Anna H E
|
|
|
23 |
8 |
p. 889-890
|
artikel
|
| 15 |
Heteroresistance to cefepime–taniborbactam in metallo-β-lactamase-encoding Enterobacterales
|
Abbott, Carter
|
|
|
23 |
8 |
p. e277-e278
|
artikel
|
| 16 |
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
|
Walia, Kamini
|
|
|
23 |
8 |
p. e301-e309
|
artikel
|
| 17 |
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
|
Juan-Giner, Aitana
|
|
|
23 |
8 |
p. 965-973
|
artikel
|
| 18 |
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
|
Kimathi, Derick
|
|
|
23 |
8 |
p. 974-982
|
artikel
|
| 19 |
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
|
Tan, Ngoc H
|
|
|
23 |
8 |
p. 901-913
|
artikel
|
| 20 |
Increasing Marburg VHF outbreaks in Africa
|
Nakkazi, Esther
|
|
|
23 |
8 |
p. e284-e285
|
artikel
|
| 21 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
23 |
8 |
p. e286
|
artikel
|
| 22 |
Iraq tackles meningitis outbreak
|
Bagcchi, Sanjeet
|
|
|
23 |
8 |
p. e282
|
artikel
|
| 23 |
Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats
|
Alakija, Ayoade
|
|
|
23 |
8 |
p. e310-e317
|
artikel
|
| 24 |
Leveraging the positives from the pandemic to strengthen infectious disease care in low-income and middle-income countries
|
Titanji, Boghuma K
|
|
|
23 |
8 |
p. 890-892
|
artikel
|
| 25 |
Marc Shamier—young doctor with a global vision
|
Kirby, Tony
|
|
|
23 |
8 |
p. 897
|
artikel
|
| 26 |
Margaret Keller
|
Bagcchi, Sanjeet
|
|
|
23 |
8 |
p. 895
|
artikel
|
| 27 |
Marta Boffito—The happy warrior
|
Kazi, Farooq
|
|
|
23 |
8 |
p. 896
|
artikel
|
| 28 |
Molecular testing in suspected infectious diarrhoea—the value of negative results
|
Wilcox, Mark H
|
|
|
23 |
8 |
p. 886-887
|
artikel
|
| 29 |
Mucosal IgA protects against BQ.1 and BQ.1.1 infection
|
Marking, Ulrika
|
|
|
23 |
8 |
p. e272-e273
|
artikel
|
| 30 |
Multidrug-resistant infections in war victims in Ukraine
|
Pallett, Scott J C
|
|
|
23 |
8 |
p. e270-e271
|
artikel
|
| 31 |
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
|
Kana, Bavesh D
|
|
|
23 |
8 |
p. e288-e300
|
artikel
|
| 32 |
Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study
|
Eyre, David W
|
|
|
23 |
8 |
p. 922-932
|
artikel
|
| 33 |
Research in brief
|
Devi, Sharmila
|
|
|
23 |
8 |
p. e287
|
artikel
|
| 34 |
RTS,S/AS01 malaria vaccine—proven safe and effective?
|
Björkman, Anders
|
|
|
23 |
8 |
p. e318-e322
|
artikel
|
| 35 |
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
|
Jenkin, Daniel
|
|
|
23 |
8 |
p. 956-964
|
artikel
|
| 36 |
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis
|
Whiley, David M
|
|
|
23 |
8 |
p. e268-e269
|
artikel
|
| 37 |
Sharing the road during the COVID-19 pandemic
|
Dunsmuir, Henrietta
|
|
|
23 |
8 |
p. 899
|
artikel
|
| 38 |
Steen Ethelberg—investigating infectious disease outbreaks
|
Samarasekera, Udani
|
|
|
23 |
8 |
p. 898
|
artikel
|
| 39 |
Sulbactam–durlobactam for Acinetobacter pneumonia
|
Mushtaq, Ammara
|
|
|
23 |
8 |
p. e283
|
artikel
|
| 40 |
Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex
|
Giuliano, Simone
|
|
|
23 |
8 |
p. e274
|
artikel
|
| 41 |
Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex – Authors' reply
|
Kaye, Keith S
|
|
|
23 |
8 |
p. e275-e276
|
artikel
|
| 42 |
The performance of rapid antigen tests against SARS-CoV-2 variants
|
Prestedge, Jacqueline
|
|
|
23 |
8 |
p. 883-884
|
artikel
|
| 43 |
The response of mpox-associated inflammatory syndrome to steroid therapy
|
Arias, Cesar A
|
|
|
23 |
8 |
p. e323-e324
|
artikel
|
| 44 |
Tuberculosis recovery in Georgia: implementing more by 24
|
Kiria, Nana
|
|
|
23 |
8 |
p. 893-894
|
artikel
|
| 45 |
Where are the long COVID trials?
|
The Lancet Infectious Diseases,
|
|
|
23 |
8 |
p. 879
|
artikel
|
| 46 |
Yeast phagocytosis by eosinophils: a case of disseminated histoplasmosis diagnosed in a peripheral blood smear
|
Camuña Correa, Javier
|
|
|
23 |
8 |
p. e325
|
artikel
|
Tijdschrift beschrijving